Allianz Asset Management GmbH Sells 3,486 Shares of United Therapeutics Corporation $UTHR

Key Points

• Allianz Asset Management GmbH has reduced its stake in United Therapeutics by 5.2%, now holding 64,090 shares valued at approximately $18.4 million.
• Insider selling was reported as COO Michael Benkowitz and CEO Martine Rothblatt sold a combined 26,500 shares for total transactions exceeding $11 million.
• Analyst price targets for United Therapeutics have been raised, with Bank of America setting a new target of $463 and ten analysts giving the stock a Buy rating.

Allianz Asset Management GmbH trimmed its position in United Therapeutics Corporation (NASDAQ:UTHR - Free Report) by 5.2% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 64,090 shares of the biotechnology company's stock after selling 3,486 shares during the quarter. Allianz Asset Management GmbH owned 0.14% of United Therapeutics worth $18,416,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently added to or reduced their stakes in the stock. Ritholtz Wealth Management boosted its position in United Therapeutics by 30.3% in the second quarter. Ritholtz Wealth Management now owns 1,075 shares of the biotechnology company's stock valued at $309,000 after buying an additional 250 shares in the last quarter. Envestnet Portfolio Solutions Inc. boosted its position in United Therapeutics by 267.6% in the second quarter. Envestnet Portfolio Solutions Inc. now owns 3,654 shares of the biotechnology company's stock valued at $1,050,000 after buying an additional 2,660 shares in the last quarter. Sequoia Financial Advisors LLC boosted its position in United Therapeutics by 60.0% in the second quarter. Sequoia Financial Advisors LLC now owns 1,067 shares of the biotechnology company's stock valued at $307,000 after buying an additional 400 shares in the last quarter. Allspring Global Investments Holdings LLC boosted its position in United Therapeutics by 2.5% in the second quarter. Allspring Global Investments Holdings LLC now owns 84,865 shares of the biotechnology company's stock valued at $24,688,000 after buying an additional 2,101 shares in the last quarter. Finally, CWM LLC boosted its position in United Therapeutics by 204.3% in the second quarter. CWM LLC now owns 5,194 shares of the biotechnology company's stock valued at $1,492,000 after buying an additional 3,487 shares in the last quarter. Institutional investors and hedge funds own 94.08% of the company's stock.

Insider Buying and Selling at United Therapeutics

In other United Therapeutics news, COO Michael Benkowitz sold 22,500 shares of United Therapeutics stock in a transaction on Monday, October 13th. The shares were sold at an average price of $440.35, for a total value of $9,907,875.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Martine A. Rothblatt sold 4,000 shares of United Therapeutics stock in a transaction on Thursday, October 16th. The shares were sold at an average price of $431.31, for a total transaction of $1,725,240.00. Following the completion of the sale, the chief executive officer directly owned 130 shares of the company's stock, valued at approximately $56,070.30. This trade represents a 96.85% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 292,435 shares of company stock valued at $118,956,307. Corporate insiders own 10.30% of the company's stock.

United Therapeutics Stock Up 0.2%

UTHR stock opened at $433.34 on Monday. The firm has a market cap of $19.55 billion, a price-to-earnings ratio of 16.91, a PEG ratio of 4.72 and a beta of 0.66. United Therapeutics Corporation has a 12-month low of $266.98 and a 12-month high of $459.48. The company's fifty day simple moving average is $385.69 and its 200 day simple moving average is $328.19.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last released its earnings results on Wednesday, July 30th. The biotechnology company reported $6.41 earnings per share (EPS) for the quarter, missing the consensus estimate of $6.80 by ($0.39). United Therapeutics had a net margin of 40.36% and a return on equity of 18.73%. The firm had revenue of $798.60 million during the quarter, compared to analyst estimates of $802.13 million. During the same quarter in the previous year, the firm earned $5.85 EPS. United Therapeutics's quarterly revenue was up 11.7% on a year-over-year basis. Research analysts expect that United Therapeutics Corporation will post 24.48 earnings per share for the current year.

Analysts Set New Price Targets

UTHR has been the topic of a number of recent research reports. Weiss Ratings reiterated a "hold (c+)" rating on shares of United Therapeutics in a report on Wednesday, October 8th. Wells Fargo & Company lifted their price target on shares of United Therapeutics from $295.00 to $414.00 and gave the stock an "equal weight" rating in a report on Wednesday, September 3rd. Cantor Fitzgerald lifted their price target on shares of United Therapeutics from $405.00 to $525.00 and gave the stock an "overweight" rating in a report on Wednesday, September 10th. Morgan Stanley lifted their price target on shares of United Therapeutics from $328.00 to $435.00 and gave the stock an "equal weight" rating in a report on Friday, October 10th. Finally, Bank of America lifted their price target on shares of United Therapeutics from $314.00 to $463.00 and gave the stock a "neutral" rating in a report on Tuesday, September 2nd. Ten analysts have rated the stock with a Buy rating and five have issued a Hold rating to the stock. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of $457.21.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.

Want to see what other hedge funds are holding UTHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for United Therapeutics Corporation (NASDAQ:UTHR - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.